Gan & Lee Pharmaceuticals specializes in the treatment of diabetes mellitus,
and has built a complete biopharmaceutical product portfolio covering long-acting, rapid-acting, and premixed insulin analogs.
The following are Gan & Lee Pharmaceuticals' core biopharmaceutical products.
Basalin®, launched in 2005, is China's first self-developed and produced basal insulin analog. A once-daily subcutaneous injection can achieve 24-hour stable glucose control; it is bioequivalent to the originator insulin glargine.
Prandilin®, launched in 2007, is China's first domestically produced rapid-acting insulin analog. It has a rapid onset of action and can quickly lower postprandial blood glucose; its efficacy and safety are consistent with the originator product.
Prandilin® 25, launched in 2014, is China's first domestically produced premixed insulin analog. It has a dual action covering both basal and postprandial blood glucose, and its efficacy and safety are consistent with the originator product.
Rapilin®, launched in 2020, is China's first domestically produced insulin aspart (a rapid-acting insulin analog). It has a rapid onset of action and can quickly lower postprandial blood glucose; its efficacy and safety are consistent with the originator product.
Rapilin® 30, launched in 2020, is China's first domestically produced insulin aspart 30 (a premixed insulin analog). It comprehensively covers both basal and postprandial blood glucose control; its efficacy and safety are consistent with the originator product.
Similin® 30, launched in 2021, is a premixed human insulin. Its structure and function are consistent with natural human insulin, and it has a dual action covering both basal and postprandial blood glucose.
Basalin® pre-filled pen, launched in 2019, is a long-acting basal insulin analog. Administered once daily, it provides 24-hour stable glucose control. The pre-filled device is easy to operate, optimizing the patient's medication experience and improving compliance.
Prandilin® pre-filled pen, launched in 2019, is a prandial insulin analog. With a rapid onset of action when injected before meals, it can quickly lower postprandial blood glucose. The pre-filled device is easy to operate, optimizing the patient's medication experience and improving compliance.
Prandilin® 25 pre-filled pen, launched in 2022, is a premixed insulin analog that can cover both basal and postprandial blood glucose. The pre-filled device is easy to operate, optimizing the patient's medication experience and improving compliance.
Rapilin® pre-filled pen, launched in 2026, is a prandial insulin analog. With a rapid onset of action when injected before meals, it can quickly lower postprandial blood glucose. The pre-filled device is easy to operate, optimizing the patient's medication experience and improving compliance.
Rapilin® 30 pre-filled pen, launched in 2026, is a premixed insulin analog that can cover both basal and postprandial blood glucose. The pre-filled device is easy to operate, optimizing the patient's medication experience and improving compliance.
